Inorganic Chemical

FDA Urges Enhanced Authority to Combat Pediatric and Neonatal Medical Device Shortages

3 months ago talkbio0Tagged Authority, Infant, Newborn, Medical Device Shortages, Pediatric brand name, regulatory, Supply Chain Vulnerabilities, United States Food and Drug Administration

FDA, Medical Device Shortages, Pediatric Patients, Neonatal Patients, Supply Chain Vulnerabilities, Regulatory Authority

Sanofi Partners with Alloy Therapeutics in $400M Deal to Advance Antisense Therapeutics

4 months ago talkbio0Tagged Alloys, Antisense, biobucks, Genetic Medicine, sanofi

Sanofi, Alloy Therapeutics, Antisense Therapeutics, Biobucks Deal, Genetic Medicine

Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

4 months ago talkbio0Tagged Alloys, AntiClastic Antisense Platform, Blood - brain barrier anatomy, Clinical Nurse Specialists, Drug Development, Genetic Medicine, RNA, sanofi

Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine

Sanofi and SK Bioscience Enhance Partnership for Next-Generation Pneumococcal Conjugate Vaccines

4 months ago talkbio0Tagged Adult, Bioscience, DKK1 gene, next-generation, PCV21, PCVs, Pediatric brand name, Phase III Testing, pneumococcal conjugate, sanofi, Vaccines

Sanofi, SK Bioscience, Pneumococcal Conjugate Vaccines (PCVs), Next-Generation Vaccines, Pediatric and Adult Populations, Phase III Testing, PCV21

Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old

4 months ago talkbio0Tagged Approved, Bardet-Biedl Syndrome, Genetic obesity, Imcivree, leptin receptor, human, Obesity, PCSK1 gene, Pediatric brand name, POMC, Rhythm, setmelanotide, United States Food and Drug Administration

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment

Mesoblast Secures FDA Approval for Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease

4 months ago talkbio0Tagged Approved, Cell Therapy, Mesenchymal Stromal Cell Therapy, Mesoblast, Pediatric brand name, Ryoncil, SR-aGVHD, Steroid-Refractory Acute Graft-Versus-Host Disease, United States Food and Drug Administration

Mesoblast, Ryoncil, FDA Approval, Mesenchymal Stromal Cell Therapy, Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD), Pediatric Patients, Cell Therapy